权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Pharmacology of Drugs of Abuse During Pregnancy

怀孕期间滥用药物的药理学

基本信息

批准号：
10688212
负责人：
JASHVANT D Unadkat
金额：
$ 153.99万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-09-01 至 2024-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10688212
关键词：
18 year old Address Adolescence Affect American Animals Brain CNR1 gene Cannabinoids Cannabis Cells Child Clinical Trials Consensus Consumption Controlled Clinical Trials Data Development Discipline of obstetrics Dose Drug Kinetics Drug Transport Ethics Exposure to Fetal Liver Fetus Frequencies Funding Future Gestational Age Glucuronides Goals Gynecology Human Impairment In Vitro Infant Infection Inhalation Knowledge Link Marijuana Maternal Exposure Mental disorders Meta-Analysis Metabolic Metabolism Methods Molecular Profiling Morbidity - disease rate Mus Neurologic Neurons Odds Ratio Organ Outcome Perfusion Pharmaceutical Preparations Pharmacology Placenta Plasma Pregnancy Pregnant Women Prevalence Proteomics Public Health Race Recommendation Risk Rodent Schizophrenia Schools Signal Transduction System THC concentration Testing Tetrahydrocannabinol Tissues Tobacco Toxic effect United States National Institutes of Health Visual attention adverse outcome age related animal data axon growth clinically relevant college data integration design developmental neurotoxicity drug disposition drug of abuse fetal fetal marijuana exposure human data illicit drug use in vivo innovation marijuana use marijuana use in pregnancy maternal marijuana use metabolome metabolomics models and simulation neonatal death neonatal morbidity neonatal outcome novel perpetrators pharmacokinetic model physiologically based pharmacokinetics placental transfer pregnant prenatal prenatal exposure programs risk prediction statistics tool unethical visual memory

项目摘要

Use of marijuana (cannabis) among pregnant women in the US is increasing with prevalence as high as 14% among 12–18 year old pregnant women. The American College of Obstetrics and Gynecology recommends that pregnant women avoid marijuana due to evidence that it affects the fetus and may interfere with brain development. Studies in animals appear to support this recommendation. Although other constituents of marijuana cannot be discounted, the general scientific consensus is that ∆9-tetrahydrocannabinol (THC), the most abundant and psychoactive component in marijuana, is the likely perpetrator of the developmental neurotoxicity of marijuana. However, these animal and in vitro studies were conducted at high THC doses or concentrations and therefore their applicability to humans, where THC plasma concentrations are sub-micromolar, is unknown. On the other hand, human data on fetal and infant developmental outcomes due to marijuana use during pregnancy are limited, confounded by other factors and remain controversial. Conducting a controlled clinical trial to determine if marijuana results in negative fetal/neonatal outcomes is unethical. Therefore, alternative approaches to determine fetal outcomes of marijuana use during pregnancy need to be explored. However, this can only be achieved when the fetal exposure to THC and its active metabolite,11-OH-THC, has been addressed and accurately predicted. To achieve this goal, we propose a systems pharmacology approach to begin to address this significant public health problem and test the central hypothesis: Maternal-fetal exposure for THC/11-OH-THC during pregnancy can be predicted through innovative in vitro and in vivo studies integrated through maternal-fetal PBPK modeling and simulation (m-f-PBPK M & S). Fetal exposure to THC/11-OH-THC will be dependent on their maternal disposition, placental transport/metabolism and fetal clearance. Fetal exposure to THC/11-OH-THC will drive their fetal toxicity. Therefore, the projects of this P01 are designed to: 1) understand fetal exposure to THC/11-OH-THC by characterizing metabolism and transport of THC/11-OH-THC in maternal organs, placenta and fetus (Project 1); 2) predict the changes in maternal exposure to THC and its comprehensive metabolome including 11-OH-THC, 11-nor-COOH-THC and the glucuronides, throughout pregnancy, and the mechanistic basis for these changes (Project 2); and 3) predict and verify gestational age- dependent placental-fetal exposure to THC/11-OH-THC through PBPK M & S by integrating the data from the above two projects (Project 3). In addition, in an exploratory manner, we will determine whether these cannabinoids produce any molecular signatures indicative of short or long-term developmental neurotoxicity in humans (Project 3). Our approach uses novel and innovative tools (e.g. m-f-PBPK model, development of an inhalational m-f-PBPK model, perfused human placenta, quantitative targeted proteomics and metabolomics) to address a compelling public health question.

在美国，孕妇吸食大麻（大麻）的人数正在增加，其流行率高达